125 related articles for article (PubMed ID: 38422592)
1. N- and s-substituted Pyrazolopyrimidines: A promising new class of potent c-Src kinase inhibitors with prominent antitumor activity.
Awaji AA; Zaloa WAZE; Seleem MA; Alswah M; Elsebaei MM; Bayoumi AH; El-Morsy AM; Alfaifi MY; Shati AA; Elbehairi SEI; Almaghrabi M; Aljohani AKB; Ahmed HEA
Bioorg Chem; 2024 Apr; 145():107228. PubMed ID: 38422592
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, design, and antiproliferative evaluation of 6-(N-Substituted-methyl)pyrazolo[3,4-d]pyrimidines as the potent anti-leukemia agents.
Chung CY; Li SM; Zeng WZ; Uramaru N; Huang GJ; Juang SH; Wong FF
Bioorg Chem; 2024 Jul; 148():107424. PubMed ID: 38728908
[TBL] [Abstract][Full Text] [Related]
3. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
5. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
6. Novel Benzyloxyphenyl Pyrimidine-5-Carbonitrile Derivatives as Potential Apoptotic Antiproliferative Agents.
Al-Mahmoudy A; Hassan A; Ibrahim T; Youssif BGM; Taher E; Tantawy M; Abdel-Aal E; Osman N
Anticancer Agents Med Chem; 2022; 22(5):978-990. PubMed ID: 34126912
[TBL] [Abstract][Full Text] [Related]
7. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biologic evaluation of novel chrysin derivatives as cytotoxic agents and caspase-3/7 activators.
Al-Oudat BA; Alqudah MA; Audat SA; Al-Balas QA; El-Elimat T; Hassan MA; Frhat IN; Azaizeh MM
Drug Des Devel Ther; 2019; 13():423-433. PubMed ID: 30774307
[TBL] [Abstract][Full Text] [Related]
9. Total Synthesis of a TNBC-Selective Cytotoxic Bromo Nor-eremophilane, PC-A, and Its Preliminary Structure-Activity Relationships.
Maeda S; Nakayama W; Saito Y; Sagano M; Goto M; Nakagawa-Goto K
J Nat Prod; 2024 Apr; 87(4):861-868. PubMed ID: 38438305
[TBL] [Abstract][Full Text] [Related]
10. Development of 2'-aminospiro [pyrano[3,2-c]quinoline]-3'-carbonitrile derivatives as non-ATP competitive Src kinase inhibitors that suppress breast cancer cell migration and proliferation.
Ramadan M; A M M Elshaier Y; Aly AA; Abdel-Aziz M; Fathy HM; Brown AB; Pridgen JR; Dalby KN; Kaoud TS
Bioorg Chem; 2021 Nov; 116():105344. PubMed ID: 34598088
[TBL] [Abstract][Full Text] [Related]
11. New Route to the Synthesis of Novel Pyrazolo[1,5-a]pyrimidines and Evaluation of their Antimicrobial Activity as RNA Polymerase Inhibitors.
Abdallah AEM; Elgemeie GH
Med Chem; 2022; 18(9):926-948. PubMed ID: 35236270
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents.
Madadi NR; Penthala NR; Ketkar A; Eoff RL; Trujullo-Alonso V; Guzman ML; Crooks PA
Anticancer Agents Med Chem; 2018; 18(4):556-564. PubMed ID: 28403783
[TBL] [Abstract][Full Text] [Related]
13. Development of Novel Class of Phenylpyrazolo[3,4-
Aljohani AKB; El Zaloa WAZ; Alswah M; Seleem MA; Elsebaei MM; Bayoumi AH; El-Morsy AM; Almaghrabi M; Awaji AA; Hammad A; Alsulaimany M; Ahmed HEA
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834474
[TBL] [Abstract][Full Text] [Related]
14. Introducing novel potent anticancer agents of 1H-benzo[f]chromene scaffolds, targeting c-Src kinase enzyme with MDA-MB-231 cell line anti-invasion effect.
Ahmed HEA; El-Nassag MAA; Hassan AH; Okasha RM; Ihmaid S; Fouda AM; Afifi TH; Aljuhani A; El-Agrody AM
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1074-1088. PubMed ID: 29923425
[TBL] [Abstract][Full Text] [Related]
15. A novel star-shaped trinuclear platinum(II) complex based on a 1,3,5-triazine core displaying potent antiproliferative activity against TNBC by the mitochondrial injury and DNA damage mechanism.
Wu Y; Zhao D; Shang J; Huang W; Chen Z
Dalton Trans; 2022 Jul; 51(29):10930-10942. PubMed ID: 35731536
[TBL] [Abstract][Full Text] [Related]
16. Thieno[2,3-d]pyrimidin-4(3H)-one Derivatives of Benzimidazole as Potential Anti- Breast Cancer (MDA-MB-231, MCF-7) Agents.
Dimov S; Mavrova AT; Yancheva D; Nikolova B; Tsoneva I
Anticancer Agents Med Chem; 2021; 21(11):1441-1450. PubMed ID: 32698751
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel pyrazolo[3,4-b]pyridine scaffold-based derivatives as potential PIM-1 kinase inhibitors in breast cancer MCF-7 cells.
Nafie MS; Amer AM; Mohamed AK; Tantawy ES
Bioorg Med Chem; 2020 Dec; 28(24):115828. PubMed ID: 33166925
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Anticancer Activity of Novel Indole Derivatives as Dual EGFR/SRC Kinase Inhibitors.
Olgen S; Biltekin Kaleli SN; Karaca BT; Demirel UU; Bristow HK
Curr Med Chem; 2023 Jun; ():. PubMed ID: 37365789
[TBL] [Abstract][Full Text] [Related]
19. Ligand-based design and synthesis of new trityl histamine and trityl cysteamine derivatives as SIRT2 inhibitors for cancer therapy.
Badran MM; Abbas SH; Tateishi H; Maemoto Y; Toma T; Ito A; Fujita M; Otsuka M; Abdel-Aziz M; Radwan MO
Eur J Med Chem; 2024 Apr; 269():116302. PubMed ID: 38484678
[TBL] [Abstract][Full Text] [Related]
20. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
Xu S; Sun X; Luo L; Yang Y; Guo Q; Tang S; Jiang Z; Li Y; Han J; Gan W; Yang F; Zhang X; Liu Y; Sun C; He J; Liu M; Zuo D; Zhu W; Wu Y
Biomed Pharmacother; 2022 Nov; 155():113537. PubMed ID: 36113258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
